GLP-1R agonists for the prevention of cardiac injury in STEMI patients undergoing PCI: Something new and promising, or not?

Publication date: December 2013 Source:IJC Metabolic & Endocrine, Volume 1 Author(s): Xian Wu Cheng , Toyoaki Murohara , Masafumi Kuzuya The incretin hormone glucagon-like peptide-1 (GLP-1) (7-36)-based therapeutic strategies have been shown to have cardioprotective properties in animal models of ischemia and infarction due to promotion of myocardial glucose uptake and suppression of cardiac cell apoptosis. However, in patient with myocardial infarct, GLP-1 analogues' capacity to effectively protect the heart from dysfunction caused by supply ischemia during percutaneous coronary intervention is still limited. We herein review routine use of a GLP-1 receptor agonist, exenatide in patients with ST-segment elevation myocardial infarction at the time of primary percutaneous coronary intervention, highlight multiple pleotrophic effects and point out several important clinical issues that require consideration and exploration.
Source: IJC Metabolic and Endocrine - Category: Endocrinology Source Type: research